Serum tissue-degrading proteinases and incident cardiovascular disease events

European Journal of Preventive Cardiology

Volumn 21, Issue 7, 2014, Pages 806-812

  Tuomainen, Anita M ^a   Kormi, Immi ^a,b   Havulinna, Aki S ^c   Tervahartiala, Taina ^a   Salomaa, Veikko ^c   Sorsa, Timo ^a   Pussinen, Pirkko J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Biomarkers; cardiovascular diseases; epidemiology; inflammation; matrix metalloproteinases

Indexed keywords

COLLAGENASE 3; LEUKOCYTE ELASTASE; MATRILYSIN; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; MMP7 PROTEIN, HUMAN; MMP8 PROTEIN, HUMAN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; FINN (CITIZEN); HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; INCIDENCE; PROTEIN BLOOD LEVEL; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE ELASTASE; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84902595154     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487312465524     Document Type: Article

References (31)

1. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006 ; 38: 306-321
2. Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 2010 ; 52: 410-428
3. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994 ; 94: 2493-2503
4. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001 ; 141: 211-217
5. Lubos E, Schnabel R, Rupprecht HJ, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J. 2006 ; 27: 150-156
6. Frantz S, Störk S, Michels K, et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail. 2008 ; 10: 388-395
7. Pussinen PJ, Sarna S, Puolakkainen M, et al. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol. 2012 ;:
8. Burke B. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology. 2004 ; 209: 51-56
9. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA. 1996 ; 93: 9748-9753
10. Lindstedt L, Saarinen J, Kalkkinen N, et al. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem. 1999 ; 274: 22627-22634
11. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation. 2006 ; 113: 438-445
12. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001 ; 104: 1899-1904
13. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006 ; 187: 161-169
14. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009 ; 105: 921-929
15. Tuomainen AM, Nyyssönen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2722-2728
16. Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999 ; 99: 2503-2509
17. Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation. 2003 ; 107: 2829-2836
18. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol. 2007 ; 82: 1420-1429
19. Cohen JR, Keegan L, Sarfati I, et al. Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients with abdominal aortic aneurysms. J Invest Surg. 1991 ; 4: 423-430
20. Hughes MF, Saarela O, Blankenberg S, et al. A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. Eur J Prev Cardiol. 2012 ; 19: 874-884
21. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005 ; 12: 132-137
22. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol. 2010 ; 39: 504-518
23. Salomaa V, Havulinna A, Saarela O, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010 ; 5: e10100 - e10100
24. Dozier S, Escobar GP, Lindsey ML. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP13. Med Chem. 2006 ; 2: 523-526
25. Cavusoglu E, Ruwende C, Chopra V, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006 ; 151: 1101.e1-1101.e8
26. Pradhan-Palikhe P, Vikatmaa P, Lajunen T, et al. Elevated MMP-8 and decreased myeloperoxidase concentrations associate significantly with the risk for peripheral atherosclerosis disease and abdominal aortic aneurysm. Scand J Immunol. 2010 ; 72: 150-157
27. Kato R, Momiyama Y, Ohmori R, et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005 ; 69: 1035-1040
28. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989 ; 320: 365-376
29. Henriksen PA, Sallenave JM. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol. 2008 ; 40: 1095-1100
30. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006 ; 1: 297-329
31. Sorsa T, Tervahartiala T, Leppilahti J, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011 ; 63: 108-113